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Abstract
Hematopoietic growth factors (HGF) are recommended therapy for high dose radiation exposure,
but unfavorable administration schedules requiring early and repeat dosing limit the logistical ease
with which they can be used. In this report, utilizing our previously described murine model of H-
ARS, survival efficacy and effect on hematopoietic recovery of unique PEGylated (PEG) HGF
developed by Bolder Biotechnology (BBT) were investigated. The PEGylated-HGF possess
longer half-lives and more potent hematopoietic properties than corresponding non-PEGylated-
HGFs. C57BL/6 mice underwent single dose lethal irradiation (7.76–8.72 Gy, 137Cs, 0.62–1.02
Gy min−1) and were treated with various dosing regimens of 0.1, 0.3 and 1.0 mg kg−1 of analogs
of humanPEG-G-CSF, murinePEG-GM-CSF, or humanPEG-IL-11. Mice were administered one
of the HGF analogs at 24–28hr post irradiation, and, in some studies, additional doses given every
other day (beginning with the 24–28hr dose) for a total of 3 or 9 doses. 30d survival was
significantly increased with only one dose of 0.3mg kg−1 of PEG-G-CSF and PEG-IL-11, or three
doses of 0.3mg kg−1 of PEG-GM-CSF (p≤0.006). Enhanced survival correlated with consistently
and significantly enhanced WBC, NE, RBC, and PLT recovery for PEG-G- and PEG-GM-CSF,
and enhanced RBC and PLT recovery for PEG-IL-11 (p≤0.05). Longer administration schedules
or higher doses did not provide a significant additional survival benefit over the shorter, lower
dose, schedules. These data demonstrate the efficacy of BBT’s PEG-HGF to provide significantly
increased survival with fewer injections and lower drug doses, which may have significant
economic and logistical value in the aftermath of a radiation event.
INTRODUCTION
The increasing presence worldwide of radioactive material for therapeutic, energy, or
weapon applications underscores the need for medical preparedness for effective treatment
in the event of accidental or intentional radiation exposure. However, there are currently no
medical countermeasures (MCM) approved to treat severely irradiated individuals, and
physicians would likely rely on medications used in chemo- and radiotherapy-induced
myelosuppression, such as hematopoietic cytokines, in addition to supportive care.
Supportive care such as antibiotics and fluids can significantly increase the lethal radiation
dose for 50% of humans at 60 days post-exposure (LD50/60) from 3.5–4.5 Gy to ~6–7 Gy
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(Lushbaugh 1969, Vriesendorp and Van Bekkum 1984, Dainiak 2002, Anno et al. 2003). As
such, supportive care will be an important factor in treating irradiated individuals. Doses in
the range of 2–10 Gy affect primarily the rapidly dividing bone marrow hematopoietic cells,
resulting in the hematopoietic (H) syndrome of the acute irradiation syndrome (H-ARS). H-
ARS is characterized by a decrease in all classes of white blood cells (WBC), erythrocytes,
and platelets, resulting in life-threatening neutropenia and thrombocytopenia, and possible
death due to infection and/or bleeding. Stimulation of the hematopoietic system with
hematopoietic growth factors (HGF) to enhance production of neutrophils and platelets
remains one of the key mitigation strategies for H-ARS.
Hematopoietic growth factors, such as granulocyte-colony stimulating factor (G-CSF), are
commonly used to accelerate recovery from chemotherapy-induced neutropenia. G-CSF has
been shown to improve survival of animals exposed to otherwise lethal radiation when
administered shortly after exposure (Schuening et al. 1989). MacVittie et al. (MacVittie et
al. 2005) reported that 17% of dogs exposed to 4 Gy and treated with vehicle survived 30
days, whereas 100% of dogs receiving daily subcutaneous (sc) injections of 0.01mg kg−1 G-
CSF for 23 days survived for 30 days. Studies in the authors’ lab (Plett et al. 2012) have
shown that daily administration of 0.125mg kg−1 G-CSF beginning 24h post-irradiation and
continuing until day 16 resulted in 65% survival of treated mice vs 30% survival in controls.
Improved survival correlated with accelerated neutrophil (NE) recovery in G-CSF-treated
animals (Plett et al. 2012).
Single administration of G-CSF or murine GM-CSF did not provide a survival benefit when
administered to lethally-irradiated mice (Neta 1988, Neta et al. 1988), unless given within 2
hours of radiation (Sureda et al. 1993). Hematopoietic growth factors used to treat
hematopoietic complications of chemotherapy, such as G-CSF, GM-CSF, and IL-11, are
typically administered by daily subcutaneous (sc) injections for 16–23 days, limiting the
attractiveness of these factors for the treatment of H-ARS in a mass casualty radiation event.
In the aftermath of such an emergency, patient numbers will be high and medical facilities
inundated, making daily treatment schedules challenging. Modification of protein
therapeutics with poly(ethylene glycol) (PEG) results in increased size, reduced renal
clearance, and prolongation of half-life (Abuchowski et al. 1984, Knauf et al. 1988,
Molineux et al. 1999, Bailon et al. 2001), thereby reducing the need for daily dosing. One
such PEGylated molecule, Neulasta (PEGylated human G-CSF, Amgen, Inc.), has
demonstrated efficacy to enhance neutrophil recovery in the treatment of drug- and
radiation-induced neutropenia in animals and humans with only one or two administrations
(MacVittie et al. 1990, Patchen et al. 1992, Welte et al. 1996, Bishop et al. 2000).
The authors have developed several novel PEGylated HGF with extended half-life and
enhanced hematopoietic efficacy compared to current therapeutics, and are evaluating these
PEG-HGF for survival efficacy in their murine model of H-ARS. Of these, human PEG-G-
CSF analog BBT-015 [Bolder Biotechnology, Inc (BBT)] possesses a longer half-life and is
capable of inducing greater and longer lasting increases in neutrophil numbers than G-CSF
or Neulasta (manuscript in preparation). Two other BBT PEG-HGFs, murine (mu) PEG-
GM-CSF analog BBT-007 and PEG-IL-11 analog BBT-059, have been shown in rodents to
possess longer half-lives and induce longer-lasting increases in hematopoietic cells than
their non-PEGylated counterparts (manuscript in preparation). The PEGylated
granulopoietic HGFs, PEG-G-CSF and PEG-GM-CSF, through their enhancement of
neutrophil recovery, offer defense against infection and are thus warranted for evaluation in
H-ARS. The PEG-IL-11 analog BBT-059 may likely speed platelet (PLT) recovery, and
may have a role in prevention of hemorrhage in HARS. Combinations of these PEG-HGFs,
with their less demanding administration schedules, offer a multi-pronged approach to
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combating the life-threatening maladies of H-ARS and may be useful in the design of
combination therapies that could further enhance survival from high dose radiation.
Efficacy studies for these new MCM will require the use of relevant, applicable and
practical animal models adhering to the Food and Drug Administration’s (FDA) Animal
Rule (AR). The author’s murine model of H-ARS in C57BL/6 mice has been extensively
defined (Plett et al. 2012) and can be conducted under Good Laboratory Practices (GLP)
when needed, as recommended by the FDA’s AR for GLP-compliant survival studies (21
CFR Part 58). In this study the authors’ model of H-ARS was utilized to demonstrate the
benefit of 1, 3, or 9 doses of PEG-G-CSF, PEG-GM-CSF, or PEG-IL-11 on survival and
hematopoietic cell recovery in lethally irradiated C57BL/6 mice.
METHODS
Mice
Specific pathogen free C57BL/6 mice (50/50 male/female; Jackson Laboratory, Bar Harbor,
Maine) were received at 10 weeks of age, an age analogous to a “young adult” human. All
studies are performed on mice of the same age to avoid age-related changes in
radiosensitivity (Grahn and Hamilton 1957, Grahn 1958, Yuhas and Storer 1967, Casarett
1968). Weights ranged from 16.0–21.6gm (females) and 19.6–28.2gm (males). Mice were
identified by ear punch and/or tail marks. All studies were approved by the Indiana
University School of Medicine Institutional Animal Care and Use Committee.
Husbandry
Up to 5 mice per cage were housed in microisolator cages on sterilized, certified direct
contact bedding (Alpha Dri) and provided certified commercial extruded lab rodent chow
(Harlan 2018SXC) ad libitum in cage hoppers and acidified water (pH 2.0–3.0) in sipper
tube bottles. Autoclaved acidified water was provided on days 4–30 post-total body
irradiation (TBI) in sipper tubes and wet feed. Animal rooms on a 12-hour light/dark cycle
were maintained at 21±3°C with 30–80% relative humidity and at least 10 air changes per
hour of 100% conditioned fresh air.
Irradiation and dosimetry
In the morning of study day 0, mice were placed in single chambers of a Plexiglas
irradiation apparatus and exposed to a single uniform total body dose between 7.76 to 8.72
Gy of gamma radiation from a 137Cs radiation source [GammaCell 40; Nordion
International, Kanata, Ontario, Canada (0.63–0.68 Gy min−1), or a Mark 1 Irradiator, JL
Shepherd, San Fernando, California (1.01–1.02 Gy min−1)]. Each cohort of mice irradiated
together was roughly divided among all treatment groups to ensure that each group received
the same irradiation exposure conditions. Dosimetry was performed as previously described
(Plett et al. 2012). Annual calibration of the radiation dose-lethality relationship in the
authors’ laboratory resulted in slightly different LDXX/30 doses over the three year time
period that the studies were conducted. Individual survival studies were conducted using two
radiation doses and results from each were combined for survival and CBC analyses as
described in the statistics section below. Specific irradiation doses and estimated LDXX/30s
used to test the PEGylated compounds were: 1) PEG-G-CSF analog BBT-015, 9 dose study:
7.76 (LD50/30) & 7.96 Gy (LD70/30); 1 dose study: 7.86 (LD60/30) & 8.10 Gy (LD80/30),
2) PEG-GM-CSF analog BBT-007, 9 dose study: 7.76 (LD50/30) & 7.96 Gy (LD70/30); 3
dose study: 7.92 (LD50/30) & 8.06 Gy (LD70/30), 3) PEG-IL-11 analog BBT-059, 3 dose
study: 7.92 & 8.06 Gy; 1 dose study 8.53 (LD50/30) & 8.72 Gy (LD70/30).
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Health status monitoring
Irradiated mice were observed for morbidity and mortality twice daily by trained laboratory
personnel and scored on a scale of zero to three for signs meeting the criteria for early
euthanasia based on three parameters: the severity of hunched posture, squinted/closed eyes,
and decreased activity, as previously described (Plett et al. 2012).
Complete blood counts (CBC)
Mice were tail-bled and CBC with differential were performed at baseline and on various
days throughout the study. Two randomly selected mice per group in different cages were
bled on d-3 to d-1 for a total of 12–14 baseline CBCs. Six to 9 randomly selected mice per
group were bled on days 10, 20, 25, and 30 (or d37 for the 1 dose PEG-IL11 study) post-
TBI. Time points for CBC were selected baased on previous studies in mice and NHP (Plett
et al. 2012, Farese et al. 2013) that show hematopoietic growth factor mitigators do not
effect the rate of the initial loss of blood cells nor the nadir, but only the recovery phase.
When possible, the same number of males and females in each group and in separate cages
were selected for bleeding and each mouse was bled a maximum of two times during the
study at least 14 days apart. CBC were also analyzed from 4–6 non-irradiated, age-matched
mice at each time point along with the study mice as an internal control. CBC were
performed using a validated HEMAVET® 950FS Hematology System (Drew Scientific,
Waterbury, CT) at least 10 mins after collection but within 24hrs.
Radiomitigator manufacture
BBT-015 (PEG-G-CSF)—The long-acting human G-CSF analog, PEG-A141C
(BBT-015), was created using site-specific PEGylation (Rosendahl et al. 2005). The protein
is homogeneously modified with a single branched, large 40 kDa maleimide-PEG at a
unique, non-essential position in the protein (amino acid 141 changed from alanine to
cysteine). In vitro bioactivity (as measured by EC50s) is within 2-fold of that of G-CSF.
BBT-015 has a 10-fold longer circulating half-life than G-CSF following subcutaneous (sc)
administration to rats and stimulates greater and longer lasting increases in circulating NE
and white blood cells (WBC) than does G-CSF or Amgen’s 20 kDA-PEG-G-CSF product
(Neulasta) in rats. BBT-015 results in faster NE recovery than G-CSF or Neulasta in
cyclophosphamide (CPA)-treated rats (manuscript in preparation). Human G-CSF is
biologically active in mice rats, dogs and non-human primates (NHP) (MacVittie et al. 2005,
Drouet et al. 2008).
BBT-007 (PEG-GM-CSF)—The long-acting murine GM-CSF analog PEG-T3C
(BBT-007) was created using site-specific PEGylation technology and is the murine
homolog of the human GM-CSF (A3C) analog described by Doherty et al. (Doherty et al.
2005). The protein is modified with a single branched 40kDa-maleimide-PEG at amino acid
position 3 (threonine changed to cysteine) of the protein chain. The murine GM-CSF protein
is used for mouse ARS studies because human GM-CSF is biologically active in dogs and
NHP (Mayer et al. 1987, Schuening et al. 1989, Mayer et al. 1990), but not active in rodents.
PEG-T3C’s in vitro bioactivity is comparable to that of murine GM-CSF. BBT-007 has a
10-fold longer circulating half-life than muGM-CSF following sc administration to rats, and
stimulates greater and longer lasting increases in circulating NE and WBC than does
muGM-CSF. BBT-007 administration causes significantly faster NE recovery than muGM-
CSF in CPA-treated rats (manuscript in preparation).
BBT-059 (PEG-IL-11)—The long-acting human PEG-IL-11 analog PEG-*179C
(BBT-059) was also created using site-specific PEGylation technology. It is modified with a
single branched 40 kDa-PEG at a cysteine residue that was added to the C-terminus of the
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protein (Lee et al. 2012). BBT-059 has an 8- to 10-fold longer circulating half-life than
IL-11 following sc or intravenous (iv) administration to rats and a single sc or iv
administration stimulates a 30–60% increase in PLT that lasts for over a week in rats. A
comparable single injection of IL-11 has no effect (manuscript in preparation). IL-11
requires multiple daily sc injections to stimulate an increase in circulating platelet levels in
rats. Human IL-11 is biologically active in mice, rats, dogs and NHP (Yang and Yang 1994,
Goldman 1995, Lee et al. 2012).
Radiomitigator administration
The radiomitigators were administered sc post-TBI as described below. Control groups were
similarly injected but with vehicle specified below. The first dose was administered no
earlier than 24h post-TBI since it would be difficult to deliver medical care to irradiated
personnel in a mass causality event earlier than 24hr post-exposure.
BBT-015 (PEG-G-CSF)—Two different administration schedules were tested, 1) 0.1 or
0.3 mg kg−1, one dose at 24+4 hours after TBI, then every other day from d1 to d17 for a
total of 9 doses, or 2) 0.3 mg kg−1 or 1.0 mg kg−1, one dose at 24+4 hours after TBI.
Vehicle: 10 mM sodium acetate, pH 4.5, 140 mM NaCl solution.
BBT-007 (PEG-GM-CSF)—Two different administration schedules were tested, 1) 0.1 or
0.3 mg kg−1, one dose at 24+4 hours after TBI, then every other day from d1 to d17 for a
total of 9 doses, or 2) 0.3 mg kg−1 or 1.0 mg kg−1, one dose at 24+4 hours after TBI, then
every other day from d1 to d5 for a total of 3 doses. Vehicle: 10 mM sodium acetate, pH 4.8,
140 mM NaCl solution.
BBT-059 (PEG-IL-11)—Two different administration schedules were tested, 1) 0.3 or 1.0
mg kg−1, one dose at 24+4 hours after TBI, then every other day from d1 to d5 for a total of
3 doses or 2) 0.3 mg kg−1 or 1.0 mg kg−1, one dose at 24+4 hours after TBI. Vehicle: 20
mM Tris, pH 7.5, 200 mM NaCl, 10% glycerol, 0.05% Tween-20 solution.
Study Design, Sample Size, & Statistical analyses
Each cage was randomized to a radiation exposure dose and individual mice were
randomized to treatment groups by a study statistician. Studies testing MCM as mitigators
were powered to detect a 30% reduction in mortality (i.e. 70% to 40%, 90% to 60%) with
80% power using a two-tailed 5% significance level. The primary outcome, 30-day survival,
was examined using logistic regression, which also included sex, radiation dose and
interactions of treatment with dose and gender to examine differential effects. Since the
randomization was by mouse, “cage effects”, if present, did not bias the results but the
model was adjusted using a Generalized Estimating Equations (GEE) method. Secondary
analysis included time to death (overall survival), and was examined using a Cox
proportional hazards regression model, which was analogous to the logistic regression and
included treatment, gender and radiation dose. Mean survival Time (MST) of decedent mice
was performed using analysis of variance including radiation dose as a factor. Unpaired
Student t-tests were also utilized to compare differences between groups.
CBC data were analyzed using a t-test to compare groups at each time point, and then
examined to see if a transformation was necessary to satisfy the assumptions of the t-test
before the analysis was implemented. In addition, data for multiple time points were
examined together in a two way analysis of variance model with time and treatment as
factors. If no treatment by time interaction exists, this analysis has more power than the t-
tests. Five mice per group yielded 80% power to detect a 2 standard deviation difference
using a two-tailed 5% significance level.
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Studies were powered to for the test of the main effect across both irradiation dose groups in
the statistical model adjusted for dose. The statistical analysis included tests for interactions
between the radiation dose and treatment for survival, MST, or CBC. If a significant
interaction (indicating a differential treatment effect for the two radiation doses) was
detected, the radiation dose groups would have been analyzed separately. The interactions
between radiation dose and treatment for survival, MST or CBC were not observed in any
these studies and therefore the results for overall tests are presented.
RESULTS
Survival of irradiated mice after BBT-015 (PEG-G-CSF) administration
The primary endpoint in survival studies utilizing the mouse H-ARS model is to assess
survival efficacy at day 30 of the candidate MCM. Fig. 1 shows a summary of all the
survival studies conducted to date using BBT PEG-HGF molecules. For ease of
presentation, day 30 survival in each study is presented as the difference in survival of the
PEG-HGF treated group to that of the vehicle group (i.e., %survival of treated - % survival
of vehicle). Results show that 9 doses of PEG-G-CSF (0.1mg kg−1 or 0.3mg kg−1 every
other day from d1 to d17 for 9 doses) significantly enhanced survival by d30 compared to
vehicle-treated mice (30d survival = 70%, 63%, and 28%, respectively, p<0.001, Fig. 1). In
the next study, one dose of PEG-G-CSF at 0.3mg kg−1 or 1.0mg kg−1 administered 24+4
hours post-irradiation also significantly increased 30 day survival compared to controls (30d
survival = 95%, 100%, and 65%, respectively, p≤0.001, Fig. 1), illustrating similar survival
efficacy of 1 dose of PEG-G-CSF as 9 doses. In addition, 0.3mg kg−1 appears to provide
similar survival efficacy as that of a 3.3-fold higher dose (1.0mg kg−1), suggesting a near
maximal response at the lower dosage.
The MST of PEG-G-CSF-treated mice was significantly decreased by 4–7 days compared to
the MST of vehicle-treated mice (Table 1, p=0.04). The shortened MST in the PEG-G-CSF-
treated mice reflects the finding that onset of death in each group occurs at approximately
the same time (day 8 in this study), but deaths in vehicle-treated mice continued to day 25,
while the last death in the PEG-G-CSF group was on day 15. Since MST is calculated only
from decedent mice, MST of groups where mice continue to die until late time points will be
increased.
“Overall Survival” is another parameter that reflects the amount of time that mice in a given
group are alive, but unlike MST, Overall Survival is calculated using both live and decedent
mice. In the current study, Overall Survival of PEG-G-CSF-treated mice was significantly
increased compared to vehicle controls (p<0.02), illustrating the overall survival benefit of
PEG-G-CSF.
Variability in expected and actual survival
The variability of expected from actual survival in our studies was 20.1±12.8% across all
studies ranging from 20% greater lethality to 44% less lethality than expected. This result
was somewhat expected, given the steep dose response curves of inbred mice (Grahn and
Hamilton 1957), compared to other species (Vriesendorp and Van Bekkum 1984). Our
previously published results in C57BL/6 mice (Plett et al. 2012) confirmed the steep dose
response curve compared to NHP (Farese et al. 2012). Given the difficulty pinpointing the
LDXX/30 in light of the small radiation dose range between LD10/30 and LD90/30, the
authors’ lab attempted to control all possible variables including room humidity and
temperature, cage location on the rack, light/dark cycles, caging, bedding, feed, vendor and
barrier selection. In addition, the radiation dose/lethality response curve was performed
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approximately annually to adjust for any variation in the radiation response of the C57BL/6
mice used in our experiments, and doses adjusted accordingly in subsequent studies.
CBC profiles of irradiated mice after BBT-015 (PEG-G-CSF) administration
CBC values of the irradiated and treated mice were assessed on day 10 (during nadir, except
for RBC, which continued to decrease until d20) shown here and in previous studies (Plett et
al. 2012), and days 20, 25, and 30 post-TBI to determine whether increased survival
correlated with enhanced hematopoietic cell recovery. While the nadir of all hematopoietic
cells at d10 post-TBI was similar for both PEG-G-CSF-treated and untreated mice, recovery
of NE, WBC, red blood cells (RBC) and PLT was significantly accelerated in mice treated
with one dose of PEG-G-CSF, compared to vehicle control (Fig. 2a–e, p≤0.05). These
differences were particularly evident for most CBC parameters at d20 post-TBI, and are
highlighted in Fig. 2f, which shows the fold increase of WBC, NE, LY, RBC, and PLT
levels in PEG-G-CSF-treated over vehicle-treated mice (p≤0.05). LY recovery was not
significantly different in treated and untreated mice in the 9 or 1 dose experiments (Fig. 2c
and 2f). Similar CBC results were obtained in the one and nine dose (data not shown), PEG-
G-CSF studies. These results suggest a predominant effect of PEG-G-CSF on cells of the
myeloid, erythroid and megakaryocytic lineage.
Survival of irradiated mice after BBT-007 (PEG-GM-CSF) administration
As observed with PEG-G-CSF, PEG-GM-CSF-treated mice receiving 0.3mg kg−1 every
other day from day one to d17, for a total of 9 doses, also exhibited significantly increased
survival (90%) at d30 post lethal irradiation compared with vehicle-treated controls (74%,
p≤0.05, Fig. 1). While 80% of mice treated with 9 doses of 0.1mg kg−1 survived (6% more
compared to vehicle controls), this did not reach statistical significance (Fig. 1). A further
study showed that just three doses of PEG GM-CSF (0.3mg kg−1 or 1.0mg kg−1) given 24+4
hours, d3, and d5 post irradiation resulted in significantly increased survival of 25–33%
more mice than vehicle-treated mice (90%, 98%, and 65%, respectively, p≤0.006, Fig. 1).
Onset and last day of death was similar between the 2 groups (12–22 days and 7–26 days for
PEG-GM-CSF and vehicle-treated mice, respectively), resulting in similar MST between
PEG-GM-CSF-treated and vehicle groups (Table 1). Overall survival, on the other hand,
was significantly increased in PEG-GM-CSF mice (p<0.04), illustrating the significantly
lower lethality in mice treated with PEG-GM-CSF.
CBC profiles of irradiated mice after BBT-007 (PEG-GM-CSF) administration
The significantly increased 30 day survival of PEG-GM-CSF-treated mice (3 doses of 0.3mg
kg−1 or 1.0mg kg−1) was correlated with significantly increased kinetics of recovery of
WBC, NE, LY, RBC, and PLT compared to controls (p≤0.006, Fig. 3a–e). Most dramatic
differences in recovery of these five CBC parameters occurred on d20 post TBI, and are
plotted as fold increase over controls in Fig. 3f (p≤0.05). As seen with PEG-G-CSF, the
nadir of hematopoietic cells (except RBC) at d10 post-irradiation was similar for both PEG-
GM-CSF treated and untreated mice, indicating that treatment with PEG-GM-CSF did not
prevent the loss of hematopoietic cells early post-TBI but was effective in promoting faster
recovery. The decline in the RBCs until d20 post-TBI was significantly more pronounced in
the vehicle-treated compared to the PEG-GM-CSF-treated groups. Similar CBC results were
observed in the three and nine dose (data not shown) PEG-GM-CSF studies. These results
document the efficacy of PEG-GM-CSF to enhance recovery of all hematopoietic lineages
in this murine model of HARS.
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Survival of irradiated mice after BBT-059 (PEG-IL-11) administration
IL-11 is a cytokine biologically active in a variety of non-hematopoietic and hematopoietic
cells, particularly megakaryocytes and platelets, and is currently used for treatment of
thrombocytopenia in cancer patients (Kaye 1998, Schwertschlag et al. 1999, Reynolds
2000). In the current studies, 3 doses of 0.3mg kg−1 or 1.0mg kg−1 PEG-IL-11 on days 1, 3,
and 5 were effective in significantly increasing 30 day survival compared to controls (98%,
92%, and 48%, respectively, p≤0.006, Fig. 1). As observed with PEG-G-CSF,
administration of just one dose of PEG-IL-11 (0.3mg kg−1 or 1.0mg kg−1 at 24+4 hours post
irradiation) also significantly increased 30 day survival compared to vehicle controls (90%,
83%, and 53%, respectively, p≤0.006, Fig. 1). The lower survival of mice treated with
1.0mg kg−1 PEG-IL-11 prompted the authors to consider that this dose might be somewhat
toxic compared to 0.3mg kg−1, so total moribund scores over 30 days were compared, but no
differences were noted (data not shown).
Similar to studies with PEG-G-CSF, the MST of PEG-IL-11-treated mice was decreased
compared to vehicle-treated mice, albeit by fewer days. Whereas MST of PEG-G-CSF mice
was ~6 days less than controls, MST of PEG-IL-11-treated mice was 3–4 days less than
controls (Table 1, p=0.03 for the 1.0mg kg−1 group). The shortened MST in PEG-IL-11-
treated mice, similar to that of PEG-G-CSF-treated mice, resulted from the fact that vehicle-
treated mice continued to die to day 25, while the last death in the PEG-IL-11 group was day
18.
Overall Survival was significantly increased in the PEG-IL-11 studies (p<0.001), again
reflecting the overall survival benefit of PEG-IL-11 as a radiomitigator in H-ARS.
CBC profiles of irradiated mice after BBT-059 (PEG-IL-11) administration
As anticipated from its known effects on hematopoiesis, the primary effect of PEG-IL-11 on
hematopoietic cell recovery was on platelets, as previously reported in mice (Du et al. 1993,
Neben et al. 1993) and in NHP (Schlerman et al. 1996), although RBC recovery was also
significantly increased in PEG-IL-11-treated mice (Figs. 4d and 4e, 1 dose of 0.3mg kg−1 or
1.0mg kg−1 24+4 hours post-irradiation, **p≤0.006). Enhanced neutrophil recovery was
only evident in mice treated with 0.3mg kg−1 PEG-IL-11 (Fig. 4b; *p≤0.05). Similar to
recovery of CBC parameters with PEG-G-CSF and PEG-GM-CSF, the most dramatic
changes in CBC parameters between PEG-IL-11 and vehicle-treated mice occurred on day
20, and are illustrated as fold change on fig. 4f (p≤0.05). Similar CBC results were observed
in the three (data not shown) and one dose PEG-IL-11-CSF studies. Also similar to PEG-G-
CSF and PEG-GM-CSF, PEG-IL-11 had no effect on the nadir of WBC, NE, and LY, while
the decline in the RBCs and PLT up to d20 post-TBI was significantly greater in the vehicle-
treated compared to the PEG-GM-CSF-treated groups.
DISCUSSION
These results demonstrate the ability of Bolder Biotechnology’s PEGylated G-CSF,
PEGylated GM-CSF, and PEGylated IL-11 to significantly enhance survival up to 100% in
lethally-irradiated mice treated with only 1 dose (PEG-G-CSF and PEG-IL-11) or 3 doses
(PEG-GM-CSF) by 24–28hr post-exposure. Survival enhancement seen with 1 to 3 doses of
these PEGylated cytokines is similar to that obtained with 16–23 daily doses of non-
PEGylated G-CSF (MacVittie et al. 2005, Plett et al. 2012) Few studies have demonstrated
significant survival efficacy after just 1–2 injections of non-PEGylated HGF, but only when
administered within hours of radiation exposure and only if delivered in combination with
other growth factors (Van der Meeren et al. 2002, Drouet et al. 2004, Van der Meeren et al.
2004, Herodin et al. 2007). Such administration protocols are challenging logistically,
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practically, and from a regulatory viewpoint since multiple MCM would likely be
represented by different companies. Single administration of MCM with a broad safety
window are most desirable for use in a radiation event.
The initial dosing regimen of 9 every other day sc injections (days 1–17) of PEG G-CSF
BBT-015 or PEG-muGM-CSF BBT-007 was chosen based partly on the authors’ (Plett et al.
2012) and other’s previous studies (Doherty et al. 2005, Rosendahl et al. 2005), showing
that daily dosing of G-CSF from day 1–16 post-TBI significantly improved survival in the
mouse HARS model. Dosing until day 16 or 17 ensures that mice receive several doses of
the drug past the neutrophil nadir, which occurs around day 10 in the mouse H-ARS model.
The authors’ used an every other day dosing regimen rather than a daily dosing regimen for
BBT-015 and muBBT-007 because of the longer in vivo half-lives of the proteins relative to
G-CSF and muGM-CSF [(Rosendahl et al. 2005) and unpublished results]. G-CSF and GM-
CSF typically are administered to cancer patients with chemotherapy-induced neutropenia
for several days after the neutrophil nadir. The second BBT-015 study used a single
injection of BBT-015 administered 24h post-TBI based on the authors’ unpublished studies
showing that a single administration of BBT-015 was sufficient to accelerate neutrophil
recovery in a rat chemotherapy-induced neutropenia model. The second muBBT-007 study
used 3 every other day injections of muBBT-007 (dosing on days 1, 3 and 5), also based on
the authors’ unpublished data showing efficacy to increase neutrophils in a rat
chemotherapy-induced neutropenia model for a related PEGylated muGM-CSF analog. A
future study will test whether a single dose of muBBT-007 administered 24h post-TBI will
improve survival in the mouse HARS model.
Van der Meeren et al. (2002) reported that daily dosing of IL-11 for 5 days beginning 2 h
post-TBI significantly improved survival of lethally irradiated mice. The first mouse H-ARS
study with PEG IL-11 BBT-059 mimicked this study by dosing the drug for 5 days post-
TBI. An every other day dosing regimen rather than a daily dosing regimen was used for
BBT-059 because of the longer in vivo half-life of BBT-059 compared to IL-11
(unpublished results). The second BBT-059 ARS study compared 3 every other day doses
(dosing on days 1, 3 and 5) with a single dose administered on day 1. A single dose of
BBT-059 was tested based on the authors’ unpublished data showing that a single injection
of PEG IL-11 BBT-059, but not IL-11, stimulated an increase in circulating platelets that
lasted for 7–10 days in rats.
The potential of combination therapy with different MCM to target H-ARS from several
mechanistic angles will likely lead to strategies with improved efficacy compared to single
administration strategies. In this regard, combination therapy with Bolder Biotechnology’s
PEGylated MCM remains an exciting possibility from both a scientific and therapeutic view,
yet to be explored.
The similarly enhanced survival seen in mice treated with the 0.3mg kg−1 and 1.0mg kg−1
doses of the three growth factors suggests that the lower 0.3mg kg−1 dose may approach
maximal effectiveness. Only IL-11 showed a slight decrease in survival at the higher dose,
suggesting possible detrimental effects of the higher dose compared to the lower dose. The
authors did not observe higher morbidity in the 1.0mg kg−1 group compared with the 0.3mg
kg−1 group, but morbidity is an indirect way of assessing toxicity. It would be useful to
include more sensitive toxicity assessments in future studies of the 1.0mg kg−1 PEG-IL-11
dose. While these studies were not powered sufficiently to detect small survival differences
between HGF-treatment groups, in the case of PEG-GM-CSF, the higher dose seemed to
provide a moderately greater survival benefit than the lower doses studied. On the other
hand, being able to utilize a lower dose may prove beneficial when combination therapies of
these three growth factors are explored, and to prevent potential side effects seen with G-
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CSF, GM-CSF and IL-11 drugs, including bone pain, various types of edema, splenic
rupture (in non myeloablated patients), or capillary leaking (Wadhwa and Thorpe 2008).
Neutralizing antibody formation by the host can be a concern in patients with intact immune
systems, but is likely not an issue in the lethally-irradiated population. Regardless, dosing
for longer periods of time could increase the chances of blocking antibodies developing,
which would result in inactivation of the therapeutic agent. Repeated dosing also requires
repeated handling of subjects, which, at least in the mouse H-ARS model, has detrimental
effects on survival (Plett et al. 2012)
An additional problem in a mass casualty event is the lack of reliable dosimetry. Current
biodosimetric methods are time-consuming and imprecise, and may not provide accurate
biological dose-estimations within a logistically- or medically-feasible time frame. This
becomes important, as the biodosimetry would direct the type of therapy that would be
appropriate. With respect to cytokine therapy, it may be safer to administer a single dose of
a PEG-HGF, shown here to be effective in mice, to individuals where the radiation exposure
level was unknown or even zero, rather than multiple daily doses which could result in side
effects such splenic rupture (Masood et al. 2008). Treatment of healthy individuals with a
PEGylated HGF has its own potential side-effect issues, as it is difficult to “undo” the long
half-life imparted by the PEG moiety. Although PEGylated cytokines have increased half-
lives, single administrations at lower doses would be less likely to induce side effects, while
being sufficient to effectively treat H-ARS symptoms. Single dose administration would
also allow quicker discharge of patients not requiring hospitalization or monitoring, but
where treatment was prescribed.
The enhanced survival observed in these studies with each of the three PEG-HGF was
strongly correlated with significantly faster recovery of CBC parameters. In addition to its
expected stimulation of neutrophil recovery (Demetri 1992), PEG-G-CSF also significantly
increased recovery of WBC, RBC, and platelets, similar to previous reports (Shimoda et al.
1993, Franzke et al. 2003). The primary targets of GM-CSF are granulocytes and
monocytes, yet PEG-GM-CSF significantly increased recovery of not only neutrophils, but
also all other hematopoietic cell types examined. PEG-GM-CSF was the only HGF in the
current study to significantly enhance recovery of lymphocytes, illustrating its broad
spectrum of hematopoietic activity. While PEG-IL-11 predictably increased recovery of its
primary target, platelets, it also enhanced recovery of RBC and in some studies, neutrophils
as well. These data are in agreement with others that documented stimulatory effects of
IL-11 on erythropoiesis, lymphopoiesis and myelopoiesis (Wadhwa and Thorpe 2008).
The authors previously reported (Plett et al. 2012) that stress effects from frequent blood
sampling for CBC (once every 5 days) and/or handling, significantly increased mortality of
lethally irradiated mice. Therefore, in the current studies, each mouse was bled a maximum
of two times during the study and each bleed was 14 days apart. It is not possible to know in
the current design whether survival was negatively impacted by even the two bleeds, but
since the control groups were bled on the same schedule, all groups should have been
similarly affected. Given the greater survival in treated groups, there does not appear to be a
detrimental effect on survival.
Despite the belief that the primary cause of death from H-ARS is infection and hemorrhage
due to neutropenia and thrombocytopenia, the general thought when considering
mechanisms for HGF-mediated survival from H-ARS is that of increased recovery of
neutrophils. In this regard, the authors’ data with PEG-IL-11 is of particular interest since
these data showed strong correlation of survival with significantly enhanced recovery of
primarily platelets and RBC, with a variable response of neutrophils. These data suggest that
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reversal of thrombocytopenia, and possibly anemia, with little or moderate recovery of
neutropenia may be sufficient to significantly increase survival from H-ARS.
These findings again highlight the potential benefit of a multi-pronged approach to HARS
mitigation with combination therapy. Enhancing the recovery of different hematopoietic cell
lineages through the use of specific HGF targeting different cell populations will
undoubtedly result in enhanced survival from H-ARS and likely push the LD50 to much
higher levels. Whether these PEG-HGF function by directly stimulating the few committed
hematopoietic stem and/or progenitors remaining after lethal radiation exposure, or rather by
indirect effects on the hematopoietic stem cell niche or other cells, remains to be
determined. Elucidation of these direct or indirect effects will need to be addressed in future
studies for complete understanding of how these MCMs are acting to increase survival and
accelerate recovery of multiple hematopoietic cell lineages. Future studies will also examine
the possible complementarity of these cytokines for increasing the recovery of all
hematopoietic lineages.
Another parameter assessed in these studies is the mean survival time (MST) of decedents,
or time to death. MST is commonly viewed as the “window of opportunity”, where MCM
are working to effect survival. Our studies show that the MST of both PEG-G-CSF and
PEG-IL-11 were significantly shorter compared to vehicle control. This finding reflects the
fact that while onset of death in both groups commences within the first two weeks after
irradiation, mice in the control group continue to die throughout the 30day time period,
while PEG-HGF-treated mice rarely expire beyond 2 weeks post-exposure.
The authors have shown that repopulation in the bone marrow begins within one week post-
TBI (Plett et al. 2012), which precedes recovery of peripheral blood cells. One mechanism
whereby PEG-HGF may exert their radiation-mitigating effects is by enhancing survival of
HSC or HPC in the marrow early after radiation exposure, resulting in increased numbers of
these important cells and more rapid expansion of blood cells during the recovery phase. If
MCM are administered too late post-exposure or not at all, HSC and HPC likely undergo
radiation-induced apoptosis due to direct effects of radiation, and/or the noxious post-
radiation microenvironment and high levels of circulating free radicals. Loss of HSC and
HPC results in a reduction of the available progenitor pool for blood cell production, thus
increasing the chances of opportunistic infection, hemorrhage, and death. PEG-HGF also
may exert their radiation-mitigating effects by stimulating expansion of lineage-specific
progeny of surviving HSC/HPC to accelerate recovery of the blood cell pool. Continued
presence of HGF post-TBI (through repeated injections of non-PEG-HGF or via prolonged
half-life of PEG-HGF) could potentially provide a dual benefit by both improving survival
of HSC and HPC and by stimulating expansion of lineage-specific progeny of the rescued
HSC/HPC. The observation that different PEG-HGFs affect recovery of different
hematopoietic cell lineages to different extents suggests that the proteins act on distinct
classes of HSC and HPC populations. This finding suggests that combination therapy with
PEG-HGFs targeting different cell populations could have additive or synergistic effects on
survival and hematopoietic recovery cell following radiation exposure. Future studies will
test this possibility.
Increasing the hematopoietic cell recovery in addition to antibiotic supportive care would
likely decrease the effect of bacterial infection either by translocation from radiation-
induced intestinal damage or from exterior sources and possible wounds inflicted by the
mass casualty event. Adding these cytokines to the care of severely irradiated individuals
should be able to not only increase survival, but also decrease morbidity and potentially
reduce the need for prolonged hospitalization. In addition, it is hoped that HGF therapy for
H-ARS may also result in long-term benefits by reducing some of the deleterious effects of
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residual bone marrow damage (RBMD) to the hematopoietic system, previously described
in survivors of this murine H-ARS model (Chua et al. 2012). Future studies will examine the
benefit of these PEG-HGF MCM on RBMD.
One aspect of this model that required continual modification, as noted by the varied
radiation doses utilized in the studies presented here, was the changing level of lethality in
the C57BL/6 mice with specific radiation doses. This problem was addressed by conducting
dose response curve experiments approximately annually to adjust the doses that would
result in the desired lethality, further refining our mouse model of H-ARS.
CONCLUSIONS
These results demonstrate that an animal H-ARS model such as the one developed in
C57BL/6 mice (Plett et al 2012) can be implemented successfully to assess MCM
effectiveness for enhancing survival, and also for assessing possible MCM mechanism of
action on hematopoietic cells. We have shown that the three PEGylated HGFs assessed in
these studies, PEG-G-CSF, PEG-GM-CSF, and PEG-IL-11 all significantly increased
survival with only one dose of 0.3mg kg−1 for PEG-G-CSF and PEG-IL-11, or as few as
three doses of 0.3mg kg−1 for PEG-GM-CSF. All three cytokines showed significantly
enhanced recovery of RBC and PLT, with the granulopoietic cytokines enhancing recovery
of WBC and NE as well. These results validate the C57BL/6 mouse H-ARS model as a
useful screening tool for assessing efficacy of potential MCM, and bringing to FDA
approval these and other potential radiation MCMs.
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Fig. 1.
Survival of irradiated mice after PEG-HGF administration. Mice were exposed to radiation
doses from 7.76 to 8.72 Gy and injected subcutaneously with either 0.1 mg kg−1 day−1, 0.3
mg kg−1 day−1, or 1.0 mg kg−1 day−1 PEG-G-CSF (BBT-015), PEG-GM-CSF (BBT-007),
or PEG-IL-11 (BBT-059) 24+4 hours (1 dose), every other day from days 1 to 5 (3 doses),
or every other day from day 1 to 17 (9 doses) post irradiation. Control mice were similarly
injected with vehicle. Bars in Fig. 1 shows the percentage of PEG-HGF-treated mice that
survived above vehicle-treated mice (% survival of treated mice minus % survival of control
mice). Thirty day survival was significantly increased for all PEG-HGF-treated mice
compared to vehicle treated mice, except for 0.1 mg/kg PEG-GM-CSF-treated mice
(*p≤0.05, **p≤0.006, n=39–40 mice per group in each study).
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Fig. 2.
Hematopoietic cell recovery in irradiated mice after PEG-G-CSF (BBT-015) administration.
C57BL/6 mice were irradiated with 7.86 or 8.10 Gy and treated with 0.3mg kg−1 or 1.0mg
kg−1 given once 24+4 hours post irradiation (panels a-e). Mice were assessed for peripheral
blood cells using a validated HEMAVET® 950FS Hematology System pre-irradiation and
post-irradiation, at time points indicated in the graphs showing mean±SEM of WBC (panel
a), NE (panel b), LY (panel c), RBC (panel d) and PLT (panel e). CBC profiles show a
significant increase in overall recovery of WBC, NE, RBC, and PLT in PEG-G-CSF-treated
mice when compared to vehicle-treated mice (**p≤0.006, n=12–13 mice in baseline time
point, n=6–8 mice per post-irradiation time point, n=4–6 mice in non-irradiated group, red
asterisks represent significant differences for 0.3mg kg−1 dose and blue asterisks for 1.0mg
kg−1 dose). Panel f shows the fold increase of all CBC parameters in PEG-G-CSF-treated
over vehicle-treated mice on d20 for both the 9 dose and 1 dose studies. Significant
increases over vehicle control were calculated from the raw CBC data and are indicated
above the bar. (*p≤0.05, **p≤0.006, n=8, for panel f, 1 equals no change).
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Fig. 3.
Hematopoietic cell recovery in irradiated mice after PEG-GM-CSF (BBT-007)
administration. C57BL/6 mice were irradiated with 7.92 or 8.06 Gy and treated with 0.3mg
kg−1 or 1.0mg kg−1 given on days 1, 3, and 5 post irradiation (panels a-e). Mice were
assessed for peripheral blood cells using a validated HEMAVET® 950FS Hematology
System pre-irradiation and post-irradiation, at time points indicated in the graph showing
mean±SEM of WBC (panel a), NE (panel b), LY (panel c), RBC (panel d) and PLT (panel
e). CBC profiles show a significant increase in overall recovery of WBC, NE, LY, RBC,
PLT in PEG-GM-CSF-treated mice when compared to vehicle-treated mice (*p≤0.05,
**p≤0.006, n=12 mice in baseline time point, n=7–8 mice per post-irradiation time point,
n=4 mice in non-irradiated group; red asterisks represent significant differences for 0.3mg
kg−1 dose and blue asterisks for 1.0mg kg−1 dose). Panel f shows fold increase of all CBC
parameters in PEG-GM-CSF-treated over vehicle-treated mice for both the 9 dose and 3
dose studies on day 20. Significant increases over vehicle control were calculated from the
raw CBC data and are indicated above the bars (*p≤0.05, **p≤0.006, n=8 for panel f, 1
equals no change).
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Fig. 4.
Hematopoietic cell recovery in irradiated mice after PEG-IL-11 (BBT-059) administration.
C57BL/6 mice were irradiated with 8.53 or 8.72 Gy and treated with 0.3mg kg−1 or 1.0mg
kg−1 given once 24+4 hours post irradiation (panels a-e). Mice were assessed for peripheral
blood cells using a validated HEMAVET® 950FS Hematology System pre-irradiation and
post-irradiation, at time points indicated in the graph showing mean±SEM of WBC (panel
a), NE (panel b), LY (panel c), RBC (panel d) and PLT (panel e). CBC profiles show a
significant increase in overall recovery of NE, RBC and PLT in PEG-IL-11-treated mice,
when compared to vehicle-treated mice (*p≤0.05, **p≤0.006, n=12–14 mice in baseline
time point, n=7–9 mice/post-irradiation time point, n=4 mice in non-irradiated group; red
asterisks represent significant differences for 0.3mg kg−1 dose and blue asterisks for 1.0mg
kg−1 dose). Panel f shows the fold increase of all CBC parameters in PEG-IL-11-treated
over vehicle-treated mice on d20 for both the 3 dose and 1 dose studies. Significant
increases over vehicle control were calculated from the raw CBC data and are indicated
above the bars (*p≤0.05, **p≤0.006, n=7–9 mice for panel f, 1 equals no change).
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Table 1
Mean Survival Time (MST) of decedent mice
Growth factor Dose (mg kg-1 day-1) MSTa (Days±SD) # of Decedent miceb Total Miceb
0.1 11.3 ± 0.4 12 40
PEG-G-CSF BBT-015
0.3 14.0 ± 4.1 17 80
1.0 NDc 0 40
Vehicle 18.5 ± 3.5d 42 79
PEG-GM-CSF BBT-007
0.1 18.6 ± 1.6 8 40
0.3 18.6 ± 2.8 8 80
1.0 18.0 1 40
Vehicle 19.7 ± 3.1 24 78
PEG-IL-11 BBT-059
0.3 16.1 ± 4.1 6 120
1.0 13.1 ± 2.7 10 79
Vehicle 18.9 ± 2.4e 62 120
aAverage of both studies for each growth factor at this dose: 9 and 1 dose for PEG-G-CSF (BBT-015); 9 and 3 dose for PEG-GM-CSF (BBT-007);
3 and 1 dose for PEG-IL-11 (BBT-059).
bNumbers reflect the sum from both studies for each growth factor at this dose as described in a above.
cND: No deaths in this group.
dSignificantly increased, when compared to all PEG-G-CSF-treated groups (p=0.04).
eSignificantly increased, when compared to all PEG-IL-11-treated groups (p=0.03).
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